|30th January 2020||Edward F Smith||2,380||Open or private sale||$2.05||$4,879.00|
|10th January 2020||Scott Braunstein||26,500||Grant/award etc.||$0.00|
|31st December 2019||Scott Braunstein||31,780||Grant/award etc.||$0.00|
|13th December 2019||Scott Braunstein||100,000||Open or private purchase||$1.25||$125,000.00|
|29th May 2019||Scott Braunstein||4,967||Grant/award etc.||$0.00|
|16th May 2019||Edward F Smith||24,211||Open or private sale||$5.03||$121,781.33|
|18th March 2019||Christopher Michael Cashman||31,662||Exercise of derivative||$1.04||$32,928.48|
|29th January 2019||Edward F Smith||2,492||Open or private sale||$3.06||$7,625.52|
|28th January 2019||Christopher Michael Cashman||8,142||Open or private sale||$3.13||$25,484.46|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw in 2003.